China moves to restrict foreign biotech acquisitions

China is proposing new restrictions on foreign acquisitions of critical biopharma technologies, as the country seeks to retain control over its burgeoning drug development industry. research legal Cancer Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Saved Stories Billing Log Out Reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Summit Search Log In Try STAT+ My Account My Account Settings Saved Stories Billing History Home Newsletter The Readout China moves…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

I might have been just as unblinking as Elizabeth during the three hours of “You Can See Everything.” Seats-edge viewing experience. What did you think?

Also: We’ll be in Madrid later this week for the European Society for Medical Oncology’s annual meeting, and we’ll be penning an ESMO in 30 Seconds newsletter. Sign up here.

Continue to STAT+ to read the full story…